Does the Choice of Bruton’s Tyrosine Kinase Inhibitor Matter for the Heart? Comparative Cardiovascular Outcomes of Ibrutinib, Acalabrutinib, and Zanubrutinib in Real-World Practice

Authors

• Rakan Alswaeer MD, Lehigh Valley Health NetworkFollow

Publication/Presentation Date

11-2026

Volume

154

Issue

1

Published In/Presented At

doi/abs/10.1161/circ.154.suppl_1.6862

Department(s)

Department of Medicine, Fellows and Residents

Document Type

Article